Clinical Trial Update: Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and immunogenicity of GSK's HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) in healthy girls 4-6 years old; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection
• Papillomavirus Infection

Drugs mentioned

• HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) (HPV-16/18 L1 VLP AS04 vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2015-05-08